Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Remission in Patients With Moderate-to-Severe Asthma and CRSwNP Treated With Dupilumab: A 24-Month Real-World Study

NCT07574294 is registered in ClinicalTrials.gov with Azienda Ulss 2 Marca Trevigiana as lead sponsor.

NCT NCT07574294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07574294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Remission in Patients With Moderate-to-Severe Asthma and CRSwNP Treated With Dupilumab: A 24-Month Real-World Study
Lead sponsor
Azienda Ulss 2 Marca Trevigiana
Phase
Observational
Overall status
Completed
Start date
June 16, 2025
Completion date
March 31, 2026
Enrollment
205 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic rhinosinusitis with nasal polyps (crswnp)